Cancer Therapies - Is the United States Always the Most Expensive Market?

Decision Resources, Inc, September 2006, Pages: 57

Introduction
The cost of innovative cancer drugs is an increasingly controversial issue. Strict price controls in many countries limit the prices that manufacturers can charge for medicines, whereas the United States’ lenient drug pricing system allows manufacturers much greater latitude to determine launch prices. However, pharmaceutical companies in all countries will need to adapt to a changing pricing environment for oncology drugs.

Get the Answers You Need to Shape Your Strategy
Concern is growing over the rising costs of cancer therapies, particularly in the United States, which has the highest drug prices overall. Have drug manufactures responded to this growing concern? Is government intervention necessary to regulate prices?

Historically, the European hospital sector allowed free pricing of drugs, even in the most heavily regulated markets. But there is a growing trend to control hospital spending on medicines. What pricing controls are being proposed and how will they affect drug pricing in European markets?
Drugs typically do not reach the Japanese market until several years after their launch in the other major pharmaceutical markets. However, Japan recently initiated measures to accelerate the launch of innovative cancer therapies. How will these measures affect future drug pricing and pricing controls in Japan?

Scope

National pricing trends: United States, France, Germany, Italy, Spain, United Kingdom, Japan

Analysis of prices of six drug classes: platinum drugs, hormonal agents, taxanes,
antimetabolites, monoclonal antibodies, and small-molecule tyrosine kinase inhibitors

Outlook and implications for manufacturers: how these trends impact drug manufactures in each market under study

Products Mentioned:
- Alemtuzumab
- Anastrozole
- Bevacizumab
- Bicalutamide
- Capecitabine
- Carboplatin
- Cetuximab
- Cisplatin
- Docetaxel
- Erlotinib
- Gefi tinib
- Gemcitabine
- Goserelin
- Imatinib
- Leuprolide
- Oxaliplatin
- Paclitaxel
- Paclitaxel (modified)
- Panitumumab
- Rituximab
- Trastuzumab

Executive Summary
Strategic Considerations
Stakeholder Implications
The Price of Cancer Therapies—A Controversial Issue
National Trends
United Statess
France
Germany
Sidebar: French Pricing System Allows High Prices for Hospital Drugs
Italy
Spain
United Kingdom
Japan
Drug Class Trends
Platinum Drugs
Hormonal Agents
Taxanes
Antimetabolites
Monoclonal Antibodies
Small-Molecule Tyrosine Kinase Inhibitors
Outlook and Implications for the Pharmaceutical Industry

List of Tables
Table 1: Launch Years for Select Cancer Therapies
Table 2: Average Annual Exchange Rates Against the U.S. Dollar, 2001-2005
Table 3: Doses Used in Pricing Calculations
Table 4: Prices of Select Cancer Therapies in the United States, 2001-2005
Table 5: Prices of Select Cancer Therapies in France, 2001-2005
Table 6: Prices of Select Cancer Therapies in France as a Percentage of U.S. Prices, 2001-2005
Table 7: Prices of Select Cancer Therapies in Germany, 2001-2005
Table 8: Prices of Select Cancer Therapies in Germany as a Percentage of U.S. Prices, 2001-2005
Table 9: Prices of Select Cancer Therapies in Italy, 2001-2005
Table 10: Prices of Select Cancer Therapies in Italy as a Percentage of U.S. Prices, 2001-2005
Table 11: Prices of Select Cancer Therapies in Spain, 2001-2005
Table 12: Prices of Select Cancer Therapies in Spain as a Percentage of U.S. Prices, 2001-2005
Table 13: Prices of Select Cancer Therapies in the United Kingdom, 2001-2005
Table 14: Prices of Select Cancer Therapies in the United Kingdom as a Percentage of U.S. Prices, 2001-2005
Table 15: Prices of Select Cancer Therapies in Japan, 2001-2005
Table 16: Prices of Select Cancer Therapies in Japan as a Percentage of U.S. Prices, 2001-2005
Table 17: Price Evolution of Cisplatin, 2001-2005
Table 18: Price Evolution of Carboplatin, 2001-2005
Table 19: Price Evolution of Oxaliplatin, 2001-2005
Table 20: Price Evolution of Leuprolide, 2001-2005
Table 21: Price Evolution of Goserelin, 2001-2005
Table 22: Price Evolution of Bicalutamide, 2001-2005
Table 23: Price Evolution of Anastrozole, 2001-2005
Table 24: Price Evolution of Paclitaxel, 2001-2005
Table 25: Price Evolution of Docetaxel, 2001-2005
Table 26: Price Evolution of Gemcitabine, 2001-2005
Table 27: Price Evolution of Capecitabine, 2001-2005
Table 28: Price Evolution of Rituximab, 2001-2005
Table 29: Price Evolution of Trastuzumab, 2001-2005
Table 30: Price Evolution of Alemtuzumab, 2001-2005
Table 31: Price Evolution of Imatinib, 2001-2005
Table 32: Evolution of Prices for Select Patent-Protected Cancer Therapies as a Percentage of 2001 Average Prices in Each Market
Table A: Cancer Therapies Granted Group Temporary Authorizations for Use in France

List of Figures
Figure 1: Price of Cisplatin as a Percentage of U.S. Price, 2005
Figure 2: Price of Carboplatin as a Percentage of U.S. Price, 2005
Figure 3: Price of Oxaliplatin as a Percentage of U.S. Price, 2005
Figure 4: Price of Leuprolide as a Percentage of U.S. Price, 2005
Figure 5: Price of Goserelin as a Percentage of U.S. Price, 2005
Figure 6: Price of Bicalutamide as a Percentage of U.S. Price, 2005
Figure 7: Price of Anastrozole as a Percentage of U.S. Price, 2005
Figure 8: Price of Paclitaxel as a Percentage of U.S. Price, 2005
Figure 9: Price of Docetaxel as a Percentage of U.S. Price, 2005
Figure 10: Price of Gemcitabine as a Percentage of U.S. Price, 2005
Figure 11: Price of Capecitabine as a Percentage of U.S. Price, 2005
Figure 12: Price of Rituximab as a Percentage of U.S. Price, 2005
Figure 13: Price of Trastuzumab as a Percentage of U.S. Price, 2005
Figure 14: Price of Alemtuzumab as a Percentage of U.S. Price, 2005
Figure 15: Price of Cetuximab as a Percentage of U.S. Price, 2005
Figure 16: Price of Bevacizumab as a Percentage of U.S. Price, 2005
Figure 17: Price of Imatinib as a Percentage of U.S. Price, 2005
Figure 18: Prices of Select Patent-Protected Cancer Therapies as a Percentage of U.S. Average Prices, 2001 and 2005

- Abraxis Bioscience
- Amgen
- AstraZeneca
- Berlex Labs
- Biogen Idec
- Bristol-Myers Squibb
- Eli Lilly
- Genentech
- ImClone Systems
- Merck KGaA
- Novartis
- Roche
- Sanofi -Aventis
- Schering AG
- TAP Pharmaceutical Products

Customers who bought this item also bought

• Global Biopharmaceutical Market Report & Forecast (2012-2017)
• Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2012
• The Incidence and Prevalence Database: Global Incidence, Prevalence, Morbidity, Comorbidity, Cost Data, Symptoms and Many Other Health Issues for over 4,500 Diseases and Procedures
• Active Pharmaceutical Ingredients (API) Global Market to 2017 - Growth in Developing Markets to Come From Cost Efficient Manufacturing and Rising Domestic Demand
• Regenerative Medicine - Global Strategic Business Report
• Nuclear Medicine - Global Strategic Business Report
• Pain Management Devices - Global Strategic Business Report
• RNA Interference (RNAi) - Global Strategic Business Report
• Pediatric Drugs and Vaccines - Global Business Strategic Report
• Hormone Replacement Therapy (HRT) - Global Strategic Business Report